bask health tirzepatide Eli Dorf (Bask Health) The 30-Week Tirzepatide Reset: One

While questions regarding long-term safety, adherence, and cost-effectiveness remain, these findings suggest that semaglutide could play an important role in cardiovascular prevention at a population level

With weekly injections, patients average 10.9% weight loss in six months

Secondary endpoints include change in neural response to visual food cues and to sweet-tasting substances as assessed by functional MRI, change in body weight, change in fat mass and change in eating behaviour and food intake

Grow your weight loss practice with compounded GLP-1 treatments

Compounded tirzepatide is not FDA-approved.

This raises an important question: Are we prepared to counsel patients on therapies that are being widely adopted outside the traditional medical framework